

BRISTOL MYERS SQUIBB CO  
Form 8-K  
December 02, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934**

**Date of Report (Date of earliest event reported): November 30, 2005**

---

**BRISTOL-MYERS SQUIBB COMPANY**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**1-1136**  
(Commission File Number)

**22-079-0350**  
(IRS Employer  
Identification Number)

**345 Park Avenue**  
**New York, NY, 10154**

(Address of Principal Executive Office)

**Registrant's telephone number, including area code: (212) 546-4000**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

On November 30, 2005, the Compensation and Management Development Committee of Bristol Myers Squibb Company (the Company) promoted John E. Celentano to President, Health Care Group, effective November 30, 2005. Mr. Celentano, 45, has held numerous positions with the Company, including Senior Director, Anti-Infectives; General Manager, Puerto Rico and the Caribbean; and Vice President and General Manager, Northern Europe. In 2002, he was promoted to President, Canada, Mexico and the Caribbean. Most recently, Mr. Celentano served as President, Latin America and Canada, for the Company's pharmaceutical business.

A copy of the press release announcing Mr. Celentano's promotion is attached to this report as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1. Press release dated December 2, 2005

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BRISTOL-MYERS SQUIBB COMPANY

Dated: December 2, 2005

By:           /s/ Sandra Leung          

Name: Sandra Leung  
Title: Secretary

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated December 2, 2005